«ÉÏһƪ/Previous Article|±¾ÆÚĿ¼/Table of Contents|ÏÂһƪ/Next Article»

¡¶ÐÄÔàÔÓÖ¾¡·[ISSN:1009-7236/CN:61-1268/R]

ÆÚÊý:

2014ÄêµÚ2ÆÚ

Ò³Âë:

233-235238

À¸Ä¿:

×ÛÊö

³ö°æÈÕÆÚ:

2014-01-20

ÎÄÕÂÐÅÏ¢/Info

Title:

Latest research progress in IIb/IIIa receptor inhibitor treatment of acute coronary syndrome

×÷Õß:

Ðì ΰ¹; 2×ÛÊö; ²Ü Þ¿¹ÉóУ

(ÍîÄÏҽѧԺ£º1.ß®í¶É½Ò½ÔºÐÄÄÚ¿Æ£¬°²»Õ Îߺþ 241001£¬2.ÐÄѪ¹ÜÄÚ¿Æ£¬°²»Õ Îߺþ 241002)

Author(s):

XU Wei¹; 2;  CAO Heng¹

(1.Department of Cardiology, Yijishan Hospital, Wuhu 241001, Anhu, China, 2.Department of Cardiology, Wannan Medical College, Wuhu 241002, Anhui, China)

¹Ø¼ü´Ê:

IIb/IIIaÊÜÌåÒÖÖƼÁ; ¼±ÐÔ¹ÚÂö×ÛºÏÕ÷; ¾­Æ¤¹Ú×´¶¯Âö½éÈëÊõ

Keywords:

IIb/IIIa receptor inhibitor;  percutaneous coronary intervention;  acute coronary syndrome

·ÖÀàºÅ:

R543.3

DOI:

-

ÎÄÏ×±êʶÂë:

A

ÕªÒª:

¼±ÐÔ¹ÚÂö×ÛºÏÕ÷(acute coronary syndrome£¬ACS)ÊÇÑÏÖØÍþвÈËÀཡ¿µµÄÒ»À༱ÐÔÐÄѪ¹Üʼþ£¬°üÀ¨²»Îȶ¨ÐÍÐĽÊÍ´¡¢·ÇS-T¶Î̧¸ßÐÔÐļ¡¹£ËÀ(non-ST-segment elevation myocardial infarction£¬NSTEMI)ºÍS-T¶Î̧¸ßÐÔÐļ¡¹£ËÀ(ST-segment elevation myocardial infarction£¬STEMI)£¬ÒÔ¼°ÒÔÉϸ÷²¡Ö¢µ¼ÖµÄâ§ËÀ¡£Ö±½Ó¾­Æ¤¹Ú×´¶¯Âö½éÈëÊõ£¨PCI£©ÒÑÏÔʾÊÇÒ»ÖÖÖÎÁÆACSµÄÓÐЧ·½·¨¡£½ÓÊÜPCIÖÎÁÆÆڼ䣬ʹÓÃÌǵ°°×IIb/IIIaÊÜÌåÒÖÖƼÁ¿ÉÒÔ¼õÉÙACS»¼ÕßѪ˨²¢·¢Ö¢µÄ·¢Éú¡£

Abstract:

Acute coronary syndrome (ACS) is a serious acute cardiovascular event threatening human health, including unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and sudden death caused by the above-mentioned cardiac problems. Direct percutaneous coronary intervention (PCI) has been proved an effective method of treatment for ACS. During PCI therapy, the use of glycoprotein IIb/IIIa receptor antagonists can reduce thrombosis complications in ACS patients.

²Î¿¼ÎÄÏ×/References

[1]Ö£ ÑÞ.ÑÎËáÌæÂÞ·Ç°àÔÚ¼±ÐÔ¹ÚÂö×ÛºÏÕ÷ÖÎÁÆÖеÄÓ¦ÓÃ[J].ÖйúÏÖ´úÒ©ÎïÓ¦ÓÃ,2011,12(5):55-56.
[2]Angiolillo DJ.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day[J].Drugs,2012,72(16):2087-2116.
[3]Armstrong PC,Peter K.GPIIb/IIIa inhibitors:from bench to bedside and back to bench again[J].Thromb Haemost, 2012,107(5):808-814.
[4]Starnes HB,Patel AA,Stouffer GA.Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions[J].Drugs,2011,71(15):2009-2030.
[5]Panduranga P,Sulaiman K.Severe thrombocytopenia following tirofiban infusion[J].Indian Pharmacol,2011,43(6):726-728.
[6]Elcioglu OC,Ozkok A,Akp¢cnar TS,et al.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review[J].Int J Hematol,2012,96(3):370-375.
[7]Âí¶«ÐÇ,Áõ»ÝÁÁ,Ò¦ºêÓ¢,µÈ.¼±ÕﾭƤ¹Ú×´¶¯Âö½éÈëÖÎÁÆÊõÖйÚ×´¶¯ÂöÄÚ×¢ÉäÑÎËáÌæÂÞ·Ç°à¶Ô¼±ÐÔST¶Î̧¸ßÐÍÐļ¡¹£ËÀ»¼ÕßÐļ¡¹à×¢¼°ÐŦÄܵÄÓ°Ïì[J].ÖйúÈ«¿Æҽѧ, 2010,13(2):476.
[8]Balghith MA.High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI-the tamip study[J].Heart Views,2012,13(3):85-90.
[9]¸ßÕñ»ª,Ô¬ÈçÓñ,Àî¹ãƽ.ÌæÂÞ·Ç°àÔÚÀÏÄê¼±ÐÔÐļ¡¹£ËÀÁÙ´²Ó¦ÓõÄÓÐЧÐÔ¼°°²È«ÐÔÑо¿[J].ÖйúÈ«¿Æҽѧ,2011,14(7):2385-2387.
[10]ĽðÐË.ÑÎËáÌæÂÞ·Ç°àÔÚ¼±ÐÔÐļ¡¹£ËÀ¼±Õï¹ÚÂö½éÈëÖÎÁÆÖеÄÓ¦ÓÃ[J].ÖйúÎóÕïѧÔÓÖ¾,2010,10(13):3049.
[11]Kubica A,Kozinski M,Navarese EP,et al.Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions[J].Curr Med Res Opin,2011,27(11):2133-2144.
[12]Desch S,Siegemund A,Scholz U,et al.Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction[J].Clin Res Cardiol, 2012,101(2):117-124.
[13]Shimada YJ,Nakra NC,Fox JT,et al.Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Am Cardiol,2012,109(5):624-628.
[14]Wang Y,Wu B,Shu X.Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction[J].Am Cardiol,2012,109(8):1124-1130.
[15]Thiele H,W?hrle J,Neuhaus P,et al.Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction(AIDA STEMI)trial[J].Am Heart J,2010,159(4):547-554.
[16]Sardella G,Sangiorgi GM,Mancone M,et al.A multicenter randomized study to evaluate intracoronary abciximab with the clearway catheter to im-prove outcomes with lysis (IC ClearLy):trial study design and ratio-nale[J].Cardiovasc Med, 2010, 11(7):529-535.
[17]Gibson CM,Maehara A,Lansky AJ,et al.Rationale and design of the INFUSE-AMI study:a 2¡Á2 factorial, randomized, multicenter, single-blind evaluation of intra-coronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-seg-ment elevation myocardial infarction[J].Am Heart,2011,161(3):478-486.
[18]De Vita M,Coluccia V,Burzotta F,et al.Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions[J].Curr Vasc Pharmacol,2012,10(4):448-453.
[19]Jing BB,Li YX,Zhang H,et al.Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina[J].Br Pharmacol,2013,169(4):848-859.

±¸×¢/Memo

±¸×¢/Memo:

ÊÕ¸åÈÕÆÚ£º2013-11-15.
ͨѶ×÷Õߣº²ÜÞ¿£¬Ö÷ÈÎҽʦ£¬Ö÷Òª´ÓÊÂÐÄѪ¹Ü²¡Ñо¿Email£ºyjscaoheng@163.com
×÷Õß¼ò½é£ºÐìΰ£¬Ë¶Ê¿ÉúEmail£º295439625@qq.com

³£Óù¦ÄÜ

¸üÐÂÈÕÆÚ/Last Update: 2014-01-16